Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Minimal clinically important differences in COPD lung function.

James F Donohue1

  • 1Division of Pulmonary Diseases and Critical Care Medicine, School of Medicine, University of North Carolina at Chapel Hill, CB# 7020, 4125 Bioinformatics Building, Chapel Hill, North Carolina 27599-7020, USA. jdonohue@med.unc.edu

COPD
|December 2, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.

International journal of chronic obstructive pulmonary disease·2023
Same author

Bridging the "Know-Do" Gaps in Five Non-Communicable Diseases Using a Common Framework Driven by Implementation Science.

Journal of healthcare leadership·2023
Same author

Current Perspectives of Pharmacotherapies for COPD.

Respiratory care·2023
Same author

Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease.

Respiratory medicine·2023
Same author

Respiratory Symptoms among US Adults: a Cross-Sectional Health Survey Study.

Pulmonary therapy·2022
Same author

Future concepts in bronchodilation for COPD: dual- <i>versus</i> monotherapy.

European respiratory review : an official journal of the European Respiratory Society·2021
Same journal

Number Needed to Treat with Biologics in Type-2 Inflammation COPD: A Systematic Review and Meta-Analysis.

COPD·2026
Same journal

Global, Regional, and National Burden of COPD Attributable to Secondhand Smoke from 1990 to 2021: Findings from the Global Burden of Disease Study 2021.

COPD·2026
Same journal

Upregulation of LncRNA MIR31HG in COPD Correlates with Disease Severity and Facilitates Inflammation via miR-342-3p.

COPD·2026
Same journal

Methodological Considerations in the Development of the AECOPD "Infection Score".

COPD·2026
Same journal

Barriers and Facilitators to Treatment Plan Adoption and Self-Management in People with Chronic Obstructive Pulmonary Disease (COPD): A Systematic Search and Narrative Synthesis.

COPD·2026
Same journal

Airway Mucus Occlusions in Ex-Smokers with and Without COPD.

COPD·2026
See all related articles

Establishing the minimal clinically important difference (MCID) for forced expiratory volume in 1 second (FEV1) is crucial for COPD management. A 100 mL change in pre-dose FEV1 appears to be a meaningful threshold for patients with COPD.

Area of Science:

  • Pulmonary Medicine
  • Clinical Trials
  • Respiratory Physiology

Background:

  • Forced expiratory volume in 1 second (FEV1) is vital for diagnosing, staging, and monitoring Chronic Obstructive Pulmonary Disease (COPD).
  • The minimal clinically important difference (MCID) represents the smallest change perceived as beneficial by patients, guiding management decisions.
  • A precise MCID for FEV1 has not been definitively established, hindering optimal patient care.

Purpose of the Study:

  • To establish a precise MCID for predose or trough FEV1 in patients with COPD.
  • To address limitations such as reproducibility, variability, and patient-specific factors influencing FEV1 measurements.
  • To provide a quantitative basis for interpreting FEV1 changes in COPD management.

Main Methods:

Related Experiment Videos

  • Utilized anchoring techniques to assess patient perception of FEV1 changes.
  • Considered factors including reproducibility, repeatability, acceptability, variability, placebo effects, and equipment effects.
  • Accounted for patient-specific variables like baseline FEV1, albuterol reversibility, and diurnal variation.

    • Main Results:

    • A change of approximately 100 mL in pre-dose FEV1 was identified as perceivable by patients.
    • This 100 mL FEV1 change correlated with reduced exacerbation relapses.
    • The observed FEV1 change is consistent with improvements seen with approved COPD bronchodilators.

    Conclusions:

    • A 100 mL change in pre-dose FEV1 may serve as a clinically meaningful threshold for COPD patients.
    • Future research should focus on consistent reporting of spirometric variables and employing statistical methods to refine MCID determination.
    • Standardized reporting and advanced statistical approaches can enhance the quantitative assessment of MCID for FEV1 in COPD.